Intellia Therapeutics, Inc. NTLA
As ofNov 20, 2026, 1:25 PM EST
- YTD
- +14.24%
- 1 year
- +27.74%
5D -0.29 (-2.79%)
- Market cap
- 1.44B
- Revenue (ttm)
- 52.89M
- EPS (ttm)
- -3.26
- Shares out
- 140.36M
- Forward P/E
- -3.53
- YTD return
- +14.24%
- 1-year return
- +27.74%
- 50-day average
- 11.75
- 200-day average
- 12.91
- Enterprise value
- 1.13B
- Volume
- 4.65M
- Avg volume
- 4.85M
- Open
- 10.18
- Previous close
- 9.52
- Day's range
- 10.05 – 10.40
- 52-week range
- 7.95 – 18.48
- Beta
- 1.82
- Analysts
- Buy
- Price target
- 22.78 (+121.8%)
- Earnings date
- Feb 25, 2027
Key statistics
- Price / sales
- 25.27
- Price / book
- 2.18
- Revenue growth
- -48.00%
- Free cash flow
- -167.19M
- Total cash
- 474.11M
- Total debt
- 230.14M
- Return on equity
- -62.60%
- Short % of float
- 39.80%
Fundamental scorecard
6 of 25 checks passed on NTLA’s reported financials
6of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 8.00
- Target (mean)
- 22.78
- Target (high)
- 61.00
- Strong buy1
- Buy9
- Hold6
- Sell2
- Strong sell2
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate -0.77727.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | -0.75 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -0.79699 | -0.91 | -0.11 | -14.18% |
| Aug 6, 2026 | Jun 30, 2026 | -0.79927 | -0.80 | 0.00 | -0.09% |
| May 11, 2026 | Mar 31, 2026 | -0.92 | -0.81 | +0.11 | +11.96% |
| Feb 26, 2026 | Dec 31, 2025 | -0.99 | -0.83 | +0.16 | +16.16% |
| Nov 6, 2025 | Sep 30, 2025 | -1.02 | -0.92 | +0.10 | +9.80% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 6, 2026 | Barclays | init | — | Underweight |
| Sep 9, 2026 | Citizens | reit | Market Outperform | Market Outperform |
| Sep 9, 2026 | Wedbush | main | Neutral | Neutral |
| Sep 9, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 25, 2026 | Citizens | reit | Market Outperform | Market Outperform |
| Aug 7, 2026 | Evercore ISI Group | up | In-Line | Outperform |
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- intelliatx.com
News
Buckle Posts Strong Q3 Results, Joins Evolent Health, Bending Spoons And Other Big Stocks Moving Higher On Friday
Intellia Therapeutics Preps Gene-Editing Launch as FDA Review Advances Intellia Therapeutics Q3 EPS $(0.91) Misses $(0.80) Estimate, Sales $7.163M Miss $10.461M Estimate
Intellia Therapeutics Completed Participant Enrollment In Its MAGNITUDE-2 Study Of ATTRv-PN
Your note
Sign in to keep a note on NTLA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BASTA JAMES EDMUND | General Counsel | Sale | Mar 1, 2026 | 156,794 |
| CHASE WILLIAM J | Director | Stock Award(Grant) | Jun 8, 2026 | 143,893 |
| CLARK ELIANA | Chief Technology Officer | Sale | Mar 1, 2026 | 93,864 |
| COHEN FREDERICK E. M.D. PH.D. | Director | Stock Award(Grant) | Jun 8, 2026 | 216,653 |
| DULAC EDWARD J III | Chief Financial Officer | Sale | Jul 21, 2026 | 148,175 |
| LEBWOHL DAVID | Officer | Stock Award(Grant) | Feb 26, 2026 | 131,192 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 11.42% | 16,035,423 | 152.66M | Sep 29, 2026 |
| ARK Investment Management, LLC | 11.35% | 15,925,221 | 151.61M | Sep 29, 2026 |
| State Street Corporation | 5.56% | 7,809,060 | 74.34M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 5.26% | 7,389,669 | 70.35M | Sep 29, 2026 |
| Shaw D.E. & Co., Inc. | 4.32% | 6,064,717 | 57.74M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.30% | 6,041,599 | 57.52M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Trust-ARK Innovation ETF | 7.88% | 11,062,565 | 105.32M | Oct 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.05% | 4,286,200 | 40.80M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 3.05% | 4,286,323 | 40.81M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.54% | 3,564,714 | 33.94M | Sep 29, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 2.40% | 3,371,851 | 32.10M | Oct 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.21% | 3,106,242 | 29.57M | Jun 29, 2026 |
